[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor

Proceedings of the National Academy of Sciences of the United States of America

Volumn 104, Issue 23, 2007, Pages 9800-9805

  Burns, H Donald ^a   Van Laere, Koen ^b   Sanabria Bohórquez, Sandra ^a   Hamill, Terence G ^a   Bormans, Guy ^c   Eng, Wai Si ^a   Gibson, Ray ^a   Ryan, Christine ^a   Connolly, Brett ^a   Patel, Shil ^a   Krause, Stephen ^a   Vanko, Amy ^a   Van Hecken, Anne ^c   Dupont, Patrick ^b   De Lepeleire, Inge ^a   Rothenberg, Paul ^a   Stoch, S Aubrey ^a   Cote, Josee ^a   Hagmann, William K ^a   Jewell, James P ^a   Lin, Linus S ^a   Liu, Ping ^a   Goulet, Mark T ^a   Gottesdiener, Keith ^a   Wagner, John A ^a   De Hoon, Jan ^c   Mortelmans, Luc ^b   Fong, Tung M ^a   Hargreaves, Richard J ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Inverse agonist occupancy

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; MK 8470; N [2 (3 CYANOPHENYL) 3 [4 (2 FLUOROETHOXY)PHENYL] 1 METHYLPROPYL] 2 (5 METHYL 2 PYRIDYLOXY) 2 METHYLPROPONAMIDE; N [2 (3 CYANOPHENYL) 3 [4 (2 FLUOROETHOXY)PHENYL] 1 METHYLPROPYL] 2 (5 METHYL 2 PYRIDYLOXY) 2 METHYLPROPONAMIDE F 18; TRACER; UNCLASSIFIED DRUG; AMIDE; DIAGNOSTIC AGENT; FLUORINE; N (3 (4 CHLOROPHENYL) 2 (3 CYANOPHENYL) 1 METHYLPROPYL) 2 METHYL 2 ((5 (TRIFLUOROMETHYL)PYRIDIN 2 YL)OXY)PROPANAMIDE; N-(3-(4-CHLOROPHENYL)-2-(3-CYANOPHENYL)-1-METHYLPROPYL)-2-METHYL-2-((5-(TRIFLUOROMETHYL)PYRIDIN-2-YL)OXY)PROPANAMIDE; PYRIDINE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; AUTORADIOGRAPHY; CAUDATE NUCLEUS; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG UPTAKE; GLOBUS PALLIDUS; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NEUROPSYCHIATRY; NONHUMAN; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RHESUS MONKEY; SUBSTANTIA NIGRA; ANIMAL; BRAIN; CHEMICAL STRUCTURE; HISTOLOGY; IMAGE PROCESSING; MACACA; METABOLISM; METHODOLOGY; ULTRASTRUCTURE;

MACACA MULATTA;

AMIDES; ANIMALS; AUTORADIOGRAPHY; BRAIN; FLUORINE RADIOISOTOPES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MACACA MULATTA; MALE; MOLECULAR STRUCTURE; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RADIOACTIVE TRACERS; RECEPTOR, CANNABINOID, CB1;

EID: 34547411013     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0703472104     Document Type: Article

References (50)

1. Rog DJ, Nurmikko TJ, Friede T, Young CA (2005) Neurology 65:812-819.
2. Walker JM, Hohmann AG, Martin WJ, Strangman NM, Huang SM, Tsou K (1999) Life Sci 65:665-673.
3. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L (2000) Nature 404:84-87.
4. Berman JS, Symonds C, Birch R (2004) Pain 112:299-306.
5. Tomida I, Pertwee RG, Azuara-Blanco A (2004) Br J Ophthalmol 88:708-713.
6. Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM (2001) Neurology 57:2108-2111.
7. Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D, Hobart J, et al. (2004) Neurology 63:1245-1250.
8. van der Stelt M, Fox SH, Hill M, Crossman AR, Petrosino S, Di Marzo V, Brotchie JM (2005) FASEB J 19:1140-1142.
9. Hill MN, Gorzalka BB (2005) Behav Pharmacol 16:333-352.
10. D'Souza DC, bi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH (2005) Biol Psychiatry 57:594-608.
11. Iversen L (2003) Brain 126:1252-1270.
12. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, et al. (2005) Science 310:329-332.
13. Glass M, Dragunow M, Faull RL (1997) Neuroscience 77:299-318.
14. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, De Costa BR, Rice KC (1990) Proc Natl Acad Sci USA 87:1932-1936.
15. Di Marzo V, Matias I (2005) Nat Neurosci 8:585-589.
16. Maldonado R, Valverde O, Berrendero F (2006) Trends Neurosci 29:225-232.
17. Lupica CR, Riegel AC (2005) Neuropharmacology 48:1105-1116.
18. Williams CM, Kirkham TC (2002) Physiol Behav 76:241-250.
19. Ravinet TC, Delgorge C, Menet C, Arnone M, Soubrie P (2004) Int J Obes Relat Metab Disord 28:640-648.
20. Gatley SJ, Gifford AN, Volkow ND, Lan R, Makriyannis A (1996) Eur J Pharmacol 307:331-338.
21. Gatley SJ, Lan R, Volkow ND, Pappas N, King P, Wong CT, Gifford AN, Pyatt B, Dewey SL, Makriyannis A (1998) J Neurochem 70:417-423.
22. Berding G, Muller-Vahl K, Schneider U, Gielow P, Fitschen J, Stuhrmann M, Harke H, Buchert R, Donnerstag F, Hofmann M, et al. (2004) Biol Psychiatry 55:904-915.
23. Berding G, Schneider U, Gielow P, Buchert R, Donnerstag F, Brandau W, Knapp WH, Emrich HM, Muller-Vahl K (2006) Psychiatry Res 147:249-256.
24. Horti AG, Fan H, Kuwabara H, Hilton J, Ravert HT, Holt DP, Alexander M, Kumar A, Rahmim A, Scheffel U, et al. (2006) J Nucl Med 47:1689-1696.
25. Donohue S, Halldin C, Finnema S, Gulyas B, Pike V (2006) NeuroImage 31:T50.
26. Herkenham M, Lynn AB, Johnson MR, Melvin LS, De Costa BR, Rice KC (1991) J Neurosci 11:563-583.
27. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, De Ceballos ML (2005) J Neurosci 25:1904-1913.
28. Herkenham M, Lynn AB, De Costa BR, Richfield EK (1991) Brain Res 547:267-274.
29. Mailleux P, Vanderhaeghen JJ (1992) Neurosci Lett 148:173-176.
30. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998) Neuroscience 83:393-411.
31. Mato S, Pazos A (2004) Neuropharmacology 46:716-726.
32. Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M (1994) Neuroscience 63:637-652.
33. Pertwee RG, Ross RA (2002) Prostaglandins Leukot Essent Fatty Acids 66:101-121.
34. Steffens M, Zentner J, Honegger J, Feuerstein TJ (2005) Biochem Pharmacol 69:169-178.
35. Pertwee RG (1997) Pharmacol Ther 74:129-180.
36. Ginovart N (2005) Mol Imaging Biol 7:45-52.
37. Lee CM, Farde L (2006) Trends Pharmacol Sci 27:310-316.
38. Kapur S, Zipursky RB, Remington G (1999) Am J Psychiatry 156:286-293.
39. Vogt BA, Laureys S (2005) Prog Brain Res 150:205-217.
40. De Jesus ML, Salles J, Meana JJ, Callado LF (2006) Neuroscience 140:635-643.
41. Gifford AN, Bruneus M, Gatley SJ, Lan R, Makriyannis A, Volkow ND (1999) J Pharmacol Exp Ther 288:478-483.
42. Hsieh C, Brown S, Derleth C, Mackie K (1999) J Neurochem 73:493-501.
43. Courts AA, Anavi-Goffer S, Ross RA, MacEwan DJ, Mackie K, Pertwee RG, Irving AJ (2001) J Neurosci 21:2425-2433.
44. Kent RS, De Lean A, Lefkowitz RJ (1980) Mol Pharmacol 17:14-23.
45. Ross EM (1989) Neuron 3:141-152.
46. Barrero FJ, Ampuero I, Morales B, Vives F, de Dios Luna Del Castillo J, Hoenicka J, Garcia Yebenes J (2005) Pharmacogenomics J 5:135-141.
47. Patel S, Hamill T, Hostetler E, Burns HD, Gibson RE (2003) Mol Imaging Biol 5:65-71.
48. Patel S, Ndubizu O, Hamill T, Chaudhary A, Burns HD, Hargreaves R, Gibson RE (2005) Mol Imaging Biol 7:314-323.
49. Koeppe RA, Frey KA, Snyder SE, Meyer P, Kilbourn MR, Kuhl DE (1999) J Cereb Blood Flow Metab 19:1150-1163.
50. Yasuno F, Brown AK, Zoghbi SS, Krushinski JH, Chernet E, Tauscher J, Shaus JM, Phebus LA, Chesterfield AK, Felder CC, et al. (March 28, 2007) Neuropsychopharmacology, 10.1038/sj.npp.1301402.